Western blot. Western blot analysis was performed to determine the expression levels of various proteins in human pancreatic cancer cells. Various cells were cultured with high-glucose Dulbecco's modified Eagle's medium (DMEM) for 48 h. Then, cells were harvested, washed with cold PBS twice, lysed with lysis buffer for 30 min on ice, and centrifuged at 12,000 rpm for 15 min at 4°C.
The total protein concentration was determined with a BCA protein assay kit (Beyotime). Equal amounts (30 μg per lane) of protein were subjected to SDS-PAGE electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. All of the blots were blocked in 10% non-fat milk and incubated with primary antibodies. Next, blots were incubated with secondary antibodies conjugated with HRP. The protein bands were developed with chemiluminescent reagents (Millipore), detected with a Bio-Rad detection system, and analyzed with Image Lab software (Bio-Rad). The primary and secondary antibodies were described as above. 5'-ATGCTATCACCTCCCCTGTGTG-3'. Cells were harvested, total RNA was extracted with Trizol, and mRNA was reverse transcribed and amplified using the SYBR PrimeScript RT-PCR kit (Invitrogen, Gaithersburg, MD) as described previously For the overexpression of cavin-1, cDNA was amplified using standard RT-PCR from RNA extracted from MiaPaCa-2 cells using the following primers: cavin-1 F:
5'-GGACTCGAGATGGAGGATGTCACGCTCCATATCGTC-3', R:
5'-TGCGAATTCCGTCGCTGTCGCTCTTGTCCACCAG-3'.
All plasmids were transduced into the target cells using lentiviral vectors (Invitrogen) as described previously 3 . Drug selection was performed using G418 or puromycin for 5-7 days. Stably transduced clones were characterized using immunoblots to detect the protein levels of mutant p53
and cavin-1. Clones with relatively high expression of the transfected genes were selected for further analyses 1 .
Cell proliferation and transwell invasion assays. Cell proliferation was assayed using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) as described previously 4 . Total cells were cultured and observed at 36 h. Results were expressed as the optical density (OD) at 490 nm.
The invasion assay was performed in 24-well BioCoat Matrigel Invasion Chambers (Corning Costar Corp., Cambridge, UK) using 5×10 5 cells in serum-free DMEM and plated onto
Matrigel-coated filters. Conditioned media supplemented with 20% fetal calf serum and NIH/3T3-conditioned media (1:1) was placed in the lower chambers as a chemoattractant. After 72 h, cells that passed through the chamber membrane were stained with Giemsa (Sigma, Rowville, VIC, Australia) and counted at ×200 magnification under a microscope (Olympus, Tokyo, Japan). Multivariate analyses, Cox proportional hazards regression model.
Abbreviations: HR, hazard ratio; CI, confidence interval; UICC, Union for International Cancer
Control; TNM, tumor-node-metastasis; NS, not significant; NA, not adopted. group I with non-mutant p53 status and low cavin-1 density (n=130 and n=37 for training cohort and validation cohort, respectively), group II with non-mutant p53 status and high cavin-1 density, or mutant p53 status and low cavin-1 density (n=58 and n=23), and group III with mutant p53 status and high cavin-1 density (n=53 and n=18).
Abbreviations: HR, hazard ratio; CI, confidence interval; UICC, Union for International Cancer Control; TNM, tumor-node-metastasis; NS, not significant; NA, not adopted. 
